Cost to Medicare of acute kidney injury in percutaneous coronary intervention

Background Acute kidney injury (AKI), including contrast-induced AKI (CI-AKI), is an important complication of per cutaneous coronary intervention (PCI), resulting in short-and long-term adverse clinical outcomes. While prior research has reported an increased cost burden to hospitals from CI-AKI, the incremental cost to payers remains unknown. Understanding this incremental cost may inform decisions and even policy in the future. The objective of this study was to estimate the short-and long-term cost to Medicare of AKI overall, and specifically CI-AKI, in PCI.Methods Patients undergoing inpatient PCI between January 2017 and June 2020 were selected from Medicare 100% fee-for-service data. Baseline clinical characteristics, PCI lesion/procedural characteristics, and AKI/CI-AKI during the PCI admission, were identified from diagnosis and procedure codes. Poisson regression, generalized linear modelling, and longitudinal mixed effects modelling, in full and propensity-matched cohorts, were used to compare PCI admission length of stay (LOS) and cost (Medicare paid amount inflated to 2022 US$), as well as total costs during 1-year following PCI, between AKI and non-AKI patients.Results The study cohort included 509,039 patients, of whom 104,033 (20.4%) were diagnosed with AKI and 9,691 (1.9%) with CI-AKI. In the full cohort, AKI was associated with + 4.12 (95% confidence interval = 4.10, 4.15) days index PCI admission LOS, + $11,313 ($11,093, $11,534) index admission costs, and + $14,800 ($14,359, $15,241) total 1-year costs. CI-AKI was associated with + 3.03 (2.97, 3.08) days LOS, +$6,566 ($6,148, $6,984) index admission costs, and + $13,381 ($12,118, $14,644) cumulative 1-year costs (all results are adjusted for baseline characteristics). Results from the propensity-matched analyses were similar.Conclusions AKI, and specifically CI-AKI, during PCI is associated with significantly longer PCI admission LOS, PCI admission costs, and long-terms costs. (Am Heart J 2023;262:20-28.)